AZNCF News and Press, AstraZeneca Plc

2024-07-25 12:25:12 ET AstraZeneca PLC (AZN) Q2 2024 Earnings Conference Call July 25, 2024, 06:45 ET Company Participants Andy Barnett - Head, IR Pascal Soriot - Executive Director & CEO Aradhana Sarin - Executive Director & CFO David Fredrickson - E...

2024-07-25 02:07:51 ET More on AstraZeneca AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings AstraZeneca's Oncology Success: Fueling Future Growth AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) Here are Big Pha...

2024-07-24 10:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Global equities rose i...

2024-07-19 06:50:00 ET Summary Parnassus Growth Equity Fund (Investor Shares) returned 3.74% (net of fees) for the quarter, underperforming the Russell 1000 Growth Index’s 8.33%. The underperformance was primarily driven by our stock selection in the Information Technology ...

2024-07-18 13:50:41 ET Summary AstraZeneca PLC will announce its Q2 earnings next Thursday, 25th July. In Q1, the company showed 19% year-on-year revenue growth and 13% EPS growth. Guidance for 2024 is for double-digit growth at the top and bottom lines — it's possible ...

2024-07-18 13:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. International equities...

2024-07-17 04:42:00 ET Summary As medical companies leverage the power of artificial intelligence, genomics, and other groundbreaking discoveries, the boundaries between technology and healthcare continue to blur, presenting potential opportunities for both patients and investors. ...

2024-07-11 13:20:00 ET Summary We have had arguably one of the more dismal six months to report to Partners. Giant spreads between us and an index or our index and other indices tend to mean revert, but as has been noted often, this has been one helluva decade as far as pace of cl...

2024-07-10 12:19:05 ET Summary argenx SE's stock is down significantly from its all-time highs due to some clinical failures for its primary asset, Vyvgart. However, recent approval for a label expansion into CIDP has turned sentiment more positive, with the shares spurting forwar...

2024-07-04 11:30:00 ET Summary This article will present an in-depth analysis of drugs being developed to combat obesity and related diseases. Pharmaceutical companies are highly interested in the global obesity treatment market, which is expected to exceed $100 billion by 2030. ...